A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer

P. Pronzato, A. Tognoni, F. Pensa, F. Vaira, A. Vigani

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to find the maximum tolerated dose of epidoxorubicin as part of a regimen with vinorelbine at the dose of 25 mg/m 2 on days 1 and 5, every 2 weeks in patients with advanced breast cancer. The optimal dose intensity of the two drugs was supported by administration of granulocyte colony stimulating factor (G-CSF) on days 7-12. Patients were treated with epidoxorubicin at three different dose levels (50-65-80 mg/m 2 on day 1 of each cycle). No dose limiting toxicity was observed in the first three patients (treated at the dose of 50 mg/m 2). We observed one case of dose limiting toxicity out of the 6 patients treated with 65 mg/m 2 and 3/3 cases among patients treated with 80 mg/m 2. We conclude that 65 mg/m 2 is the maximum tolerated dose of epidoxorubicin in this regimen, which is also able to maintain adequate dose intensities.

Original languageEnglish
Pages (from-to)326-330
Number of pages5
JournalJournal of Chemotherapy
Volume10
Issue number4
Publication statusPublished - 1998

Keywords

  • Advanced breast cancer
  • Breast cancer
  • Epidoxorubicin
  • Granulocyte colony stimulating factor
  • Vinorelbine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer'. Together they form a unique fingerprint.

Cite this